Two months after a National Company Law Tribunal (NCLT) issued an order initiating corporate insolvency proceedings against debt-ridden Orchid Pharma, numerous potential suitors, including top private equity players and...
M&A deals in pharma sector decline in 2017 amid tough business conditions
Pharmaceutical companies have become cautious with regard to mergers and acquisitions (M&As) as the business environment remains challenging due to pricing pressure and regulatory interventions in key markets—the US...
Piramal invests $55 million to upgrade API plants
In a boost to its contract manufacturing business, Piramal Enterprises has invested $55 million (around Rs 360 crore ) to upgrade its active pharmaceutical ingredient manufacturing plants in India and the US. Healthcare...
Novartis divests anti-infectives brands to Samara Capital
Global pharma major NovartisBSE -0.31 % AG today said it has divested some of its anti-infectives brands mainly catering to the women’s healthcare to private equity firm Samara Capital for an undisclosed sum. The...
Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billion
Chinese drug firm Fosun Pharma has acquired approximately 74 percent in Hyderabad-based Gland Pharma at a valuation of not more than USD 1.09 billion, the company has said. Since all the conditions precedent of the...
After Gland, Chinese pharma giant Fosun eyes API maker Symbiotec
Weeks after Chinese pharmaceutical giant Fosun tweaked its acquisition of Hyderabad-based Gland Pharma for $1 billion (Rs 6,500 crore), it is out shopping again to further strengthen its India presence. Shanghai-based...
Abbott wins U.S. antitrust approval to buy Alere with conditions
Abbott Laboratories has won U.S. antitrust approval to buy Alere Inc on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday. Canada also announced on...
Novartis India board clears share buyback worth Rs 231 cr
Drug firm Novartis India on Monday said its board has approved buyback of up to 34.5 lakh shares, accounting for about 12.26 percent of the existing paid up capital of the company, for up to Rs 231.15 crore. The...
Mankind Pharma looking to sell 15 per cent stake; PE funds make a bee-line
Delhi based Mankind Pharma, one of India’s top pharmaceutical companies and maker of leading brands like Manforce condoms, PregaNews & Unwanted 72 is eyeing a mega fundraising round, multiple sources familiar...
Generic drugmaker Impax Labs in talks to merge with Amneal: WSJ
Impax Laboratories Inc (IPXL.O) is in talks to merge with privately held Amneal Pharmaceuticals LLC, the Wall Street Journal reported on Thursday, citing people familiar with the matter. The generic drugmaker’s shares...
Catalent bolsters biopharma business with Cook Pharmica buy
U.S. drug contract manufacturer Catalent Inc (CTLT.N) agreed to buy Cook Pharmica LLC for $950 million in cash as the company doubles down on its fast-growing business of supplying biologics to drugmakers. Catalent’s...
Teva Pharma to sell more women’s health assets for $1.38 billion
Teva Pharmaceutical Industries Ltd (TEVA.N) (TEVA.TA) said on Monday it would sell the remaining assets in its specialty women’s health business for $1.38 billion in two separate transactions. Israel-based Teva will use...
